Use should be restricted to clinical trials; other options are recommended for non-severe COVID-19, including nirmatrelvir–ritonavir (Paxlovid) and remdesivir.
The Public Health Agency of Canada says the disease is mainly being transmitted among men who report intimate contact with men, but anyone can get monkeypox.